Glucocorticoids and mineralocorticoids have distinct in vivo roles despite close structural homology and similarities in vitro. Known mechanisms of specificity focus on factors extrinsic to the receptor; interactions that directly regulate the receptor to confer specificity are less well understood, particularly for the mineralocorticoid receptor (MR).
T HE MINERALOCORTICOID receptor (MR) and the glu-
cocorticoid receptor (GR) are closely related members of the steroid receptor superfamily (1) . As with other members of the superfamily, the majority of the sequence variability and, by inference, receptor specificity, resides in the N-terminus, whereas the DNA-binding (DBD) and ligandbinding (LBD) domains are relatively homologous, sharing 94% and 57% identity, respectively (1) . This sequence conservation is reflected in their overlapping functions, both in vitro and in vivo.
In vitro, the GR and MR differentiate poorly between both their respective cognate ligands and hormone response elements. Although the mineralocorticoid aldosterone binds to the MR with relative specificity, the physiological glucocorticoid cortisol (or corticosterone in rodents) binds to both MR and GR. Although the maximal level of transactivation by the GR is 10-fold greater than that by the MR (a difference mediated by the N-terminus of the GR), receptor binding and transactivation by the MR occur at 10-fold lower concentrations of cortisol those by the GR (2) (3) (4) (5) . The promiscuous binding and activation of simple glucocorticoid response elements (GRE), such as those within the mouse mammary tumor virus (MMTV) long terminal repeat promoter, reflect the near identity of the DBD of the GR and MR as well as that of the androgen receptor and progesterone receptor. Specific androgen response elements (6, 7) have been identified; however, the identification of a specific mineralocorticoid response element, or indeed of a directly MR-regulated gene, remains elusive. Domain swap experiments in which the DBD of the MR and that of the GR are exchanged were unable to identify any difference in the transactivation of simple promoters, implying functional equivalence of the DBD (2, 4) , at least at these response elements. On the basis of these studies, it has been suggested that MR and GR could be viewed as high and low affinity corticosteroid receptors, rather than as specific receptors for mineralocorticoids and glucocorticoids.
In vivo, mineralocorticoids and glucocorticoids have both distinct and overlapping physiological effects. Both mineralocorticoids and glucocorticoids regulate sodium and water absorption across epithelial tissues such as the kidney and colon, and thus indirectly affect blood pressure. However, the mechanisms by which they regulate sodium and potassium transport, at least in the distal colon, differ (8, 9) . Clearly, distinct roles for MR and GR occur at nonepithelial tissues. Glucocorticoids act independently of mineralocorticoids on diverse processes such as inflammation, bone turnover, and glucose metabolism, whereas specific roles for the MR independent of GR action, include central blood pressure regulation (10) , modulation of neuronal excitability (11) , and stimulation of cardiac fibrosis (12) . Indeed, MR and GR have directly opposite effects on neuronal excitability (11) .
Mineralocorticoid specificity in vivo is conferred in part by restriction of ligand availability. The enzyme 11␤-hydroxysteroid dehydrogenase type 2 (11␤HSD2) converts cortisol to its inactive metabolite cortisone, whereas a C11,18-hemiketal group renders aldosterone resistant to the enzyme; thus, despite circulating concentrations of aldosterone 1000-fold lower than those of cortisol, the MR is selectively activated by mineralocorticoids in epithelial tissues such as the kidney (13, 14) . In addition, although the expression and function of the GR appear ubiquitous, the MR is expressed in high abundance only in the hippocampus, brain stem, kidney, and distal colon (1, 3, 15) . MR and GR, however, are coexpressed in several sites where 11␤-HSD2 is not expressed (16) , yet both receptors have distinct roles (10 -12) . This suggests that the above mechanisms, although clearly important, do not fully account for specificity.
Pearce and Yamamoto (17) demonstrated that GR, but not MR, inhibits transactivation by the transcription factor activating protein-1 at the complex GRE of the proliferin promoter. Thus, GR-specific responses can occur at a complex response element despite the lack of an observed specific response at a simple GRE (2, (3) (4) (5) . Although differences mediated by such cellular factors might play a role in distinguishing between the GR and the MR, other examples have yet to be described. Despite evidence from studies of other steroid receptors that the cellular milieu might place contextual constraints on the specificity of the response, comparative studies of GR and MR in vitro have primarily been carried out in the fibroblast-derived simian renal cell line, CV-1.
We sought to determine whether the apparent paucity of the MR response relative to that of the GR response was indeed intrinsic to the receptor, and to identify particular cellular contexts that might be a more accurate reflection of in vivo function. We compared relative transactivation by the GR and the MR in three cell lines: CV-1 cells; a porcine renal epithelial cell line, LLC-PK1 (18); and a neuronal medullary raphe line, RN33B (19) . The LLC-PK1 cell line has characteristics of both proximal and distal convoluted tubules (18, 20) , and the RN33B cell line was derived from cells with neuronal precursor markers in the central nervous system of the embryonal rat (19) . In the renal tubular and neuronal cell lines, the maximal response of the MR relative to that of the GR is enhanced up to 3-fold. Novel cell-specific differential regulation through altered ligand sensitivity was also observed. Chimeric receptor analysis suggests that intercellular variability in ligand sensitivity is conferred by the N-terminus, possibly via cellular factors and independently of receptor-ligand binding.
Materials and Methods Materials
The steroids [cortisol (Solu-cortef, Upjohn, Sydney, Australia) and aldosterone and dexamethasone (Sigma Chemical Co., St. Louis, MO)] were initially diluted in alcohol to 0.1 m, then serially diluted in PBS in 10-fold dilutions and stored at 4 C.
Plasmids
pRShGR NX (2, 21) and pRShMR NX (1, 2) were gifts from Prof. R. Evans (The Salk Institute, La Jolla, CA). These receptors contain artificial NotI and XhoI restriction sites, originally introduced to facilitate construction of chimeric receptors, at either end of the DBD of the wild-type receptor. The magnitude of transactivation by MR, compared to that of GR, increases in CV-1 cells from 10% for the wild-type receptors to 20% with the modified constructs (2 
Cell culture and transfections
One microgram of MMTV-LUC and 1 g RSV-CAT together with 1 g of one of the expression plasmids (GR, MR, or a chimeric receptor) were cotransfected into CV-1, LLC-PK1, or RN33-B cells by either the calcium phosphate method (CV-1 and LLC-PK1) (21) or electroporation (RN33-B cells). CV-1 cells are derived from African green monkey renal fibroblasts and have conventionally been used in most similar studies. These were initially obtained from Dr. G. Muscat (University of Queensland, Brisbane, Australia); experiments were later repeated using cells from the American Type Culture Collection (Rockville, MD), and the results were essentially similar. LLC-PK1 (CSL, Parkville, Australia) is a porcine renal epithelial line that has mixed characteristics: glucose transport characteristics of the proximal convoluted tubule, adenylate cyclase responsivity to vasopressin and calcitonin (as in the thick medullary ascending limb), and the high transepithelial resistance of collecting ducts (18, 20) . RN33B cells are derived from day 12 embryonic rat medullary raphe, which express neurofilament markers and neuronal precursor, but not glial cell markers, and have the capacity for further neuronal differentiation (19) . These were generously provided by Prof. S. Whittemore (University of Miami, Miami, FL). Experiments using the GR:MR chimeric receptors were conducted in CV-1 and LLC-PK1 cells only.
Cells were grown in DMEM (Trace Biosciences, Sydney, Australia) supplemented with 4.5 g/liter glucose, 1 mm glutamine, nonessential fatty acids, 1% penicillin-streptomycin (CSL), and 5% (CV-1) or 10% (LLC-PK1 and RN33B) charcoal-stripped FBS. The RN33B cells were maintained at 33 C; the other lines were maintained at 37 C. Calcium phosphate transfections were performed 20 -24 h after the cells had been trypsinized and replated at cell densities of 2 ϫ 10 5 and 3.5 ϫ 10 5 /35-mm 2 plate for CV-1 and LLC-PK1 cells, respectively. Electroporation was performed at 260 V, 25 mA, 25 mW, and 1000 farads with an Invitrogen electroporator (Invitrogen, San Diego, CA). Steroids were added 16 -20 h after transfection. RN33B cells were harvested 48 h later; the other cells were harvested after 24 h. The cells were then lysed in reporter lysis buffer (Promega, Madison, WI). Luciferase activity was measured with a Berthold luminometer (Berthold, Wildbad, Germany); CAT activity was assayed as a measure of transfection efficiency (21) and used to correct for differences in transfection efficiency between individual wells. Transcriptional activity was calculated by correcting luciferase results for transfection efficiency with the CAT activity, then expressed as a percentage of the maximal cortisol or dexamethasoneinduced GR activity within each individual cell line. All transfections were performed with two independent points in at least three independent experiments; the results shown are the means and ses of these values. Results of individual experiments, including the cell-specific shifts in ligand sensitivity, correlated well with the means.
Binding studies
CV-1 and LLC-PK1 cells were transiently transfected with pRShGR NX in concentrations equivalent to those used in the transactivation studies (10 g plasmid/80-mm 3 flask). Transfections were performed using the calcium phosphate method (21) , 10 Ϫ9 , 5 ϫ 10 Ϫ10 , and 2.5 ϫ 10 Ϫ10 m for LLC-PK1 cells. The cells were then washed thrice in 1% BSA in PBS, and activity was measured using a liquid scintillation assay. Nonspecific binding was measured, also in triplicate as described above, by the concurrent addition of cold dexamethasone in a 500-fold excess, and specific binding was calculated by subtracting nonspecific counts from total counts.
Results

Receptor-specific cellular variations in transactivational activation and ligand sensitivity
To compare cellular differences in transcriptional responses mediated by hGR and hMR, we constructed hormone-response profiles by cotransfecting either hGR or hMR together with the reporter genes MMTV-LUC and RSV-CAT into the CV-1 line, the renal epithelial LLC-PK1 cell line, and the central nervous system medullary raphe RN33B cell line. In agreement with previous reports in CV-1 (23) and LLC-PK1 cells (24) , a ligand-induced transcriptional response in the absence of transfected GR or MR was not detected in these cell lines, indicating an absence of endogenous GR or MR (data not shown). The responses obtained with the physiological ligand cortisol, which binds to and activates both receptors, are shown in Fig. 1 . The dose-response curves for the CV-1 cells agrees with previously reported data; the ED 50 for the hGR and the hMR were 33 and 1.4 nm, respectively, and the concentrations that elicited a maximum response (E max ) were 100 and 30 nm, respectively (2, 4, 5) . Maximal MR activity is about 20% that of the GR, which is consistent with previous studies in CV-1 (5) and neuroblastoma SK-N-MC cells (2) using similar GR and MR expression plasmids.
When the responses in the other two cell lines were compared to those in CV-1 cells, two particular aspects differed: ligand sensitivity and the maximal transcriptional response of the MR relative to the GR ( Fig. 1 and Table 1 ). The maximal MR-mediated response to cortisol, relative to that of the GR, after correction for variations in transfection efficiency between cell lines was significantly increased to 63% of the maximal GR response in LLC-PK1 cells (P Ͻ 0.001) and to 51% in RN33B cells (P Ͻ 0.001) relative to that in CV-1 cells (23%). If, rather than using absolute values, the responses were expressed as fold increases over baseline (transactivation in the absence of ligand), the pattern was essentially the same. Cortisol elicited a 116-fold increase in the activity of the MR in CV-1 cells, 19% of the response of the GR (600-fold). Induction of the MR in LLC-PK1 cells (62-fold) was nearly equivalent to that of the GR (66-fold), whereas in RN33B cells the MR induction (40-fold) was 40% that of the GR (100-fold).
Unexpectedly, the dose-response curve for cortisol-stimulated transactivation by GR was consistently shifted to the left in LLC-PK1 cells (ED 50 ϳ4 nm) and to the right in RN33B cells (ED 50 ϳ250 nm) relative to that in CV-1 cells (ED 50 ϳ33 nm). The GR in the renal epithelial LLC-PK1 cells was thus activated at concentrations of cortisol about 10-fold lower than those required in CV-1 cells and 50-to 100-fold lower than those in RN33B cells. In marked contrast, the cell-specific variation in MR sensitivity to cortisol was small; the ED 50 values for CV-1 and RN33B cells were nearly identical and varied by less than 3-fold in LLC-PK1 cells (Table 1) .
In vivo, the specificity of aldosterone access to the MR is conferred by inactivation of cortisol by 11␤HSD2 (13, 14) . Addition of the 11␤HSD2 inhibitor carbenoxolone (10 Ϫ5 m) did not reduce the magnitude of transactivation or shift the dose-response curve significantly in either cell line (data not shown), in agreement with the reports of Leckie et al. (24) and Lombès et al. (25) . To further confirm that the shift of the cortisol response was neither specific to cortisol nor an effect Transcriptional activity has been calculated from the luciferase activities as in Fig. 1 . MR/GR activity refers to the ratio of the magnitude of maximal transactivation. Each result is the mean Ϯ SEM of at least three independent experiments performed in duplicate. The E max of the MR in LLC-PK1 cells is less clearly definable due to the biphasic response, but is taken as the first peak (Fig. 2) .
a P Ͻ 0.001 vs. CV-1 cells. b P Ͻ 0.05 vs. RN33B cells.
of endogenous 11␤HSD2, we repeated these experiments using the synthetic glucocorticoid dexamethasone for the GR and aldosterone for the hMR (Fig. 2) . We observed the same shift in the dose-response curves for the GR with dexamethasone in all cell lines, which also argues that 11␤HSD2 activity did not account for the altered ligand sensitivity of the GR. As with cortisol, the variation in the sensitivity of the MR to aldosterone was minor, particularly between LLC-PK1 and RN33B cells, and was probably due to nonspecific effects, such as small differences in cell density between experiments.
Rather surprisingly, the cortisol-activated MR had a biphasic response in LLC-PK1 cells, making estimation of the ED 50 value difficult. The response was consistent in each individual experiment. The initial fall in transactivation for cortisol was noted at two consecutive points (P Ͻ 0.05), and the subsequent rise was also detected at two consecutive points. A similar, but nonsignificant, trough was also observed with aldosterone in these cells. We cannot at this time provide an adequate explanation for this cell-specific phenomenon, although it is not explained by the presence of an endogenous receptor.
Binding affinities of hGR in CV-1 and LLC-PK1 cells
The binding affinity of the GR for the glucocorticoid dexamethasone was compared in CV-1 and LLC-PK1 cells to examine whether this could account for the alterations in ligand sensitivity. hGR was transfected into CV-1 and LLC-PK1 cells, and binding affinities were calculated using [ 3 H]dexamethasone. The binding affinity of the GR in the LLC-PK1 cells, as determined by Scatchard analysis (Fig. 3) , was approximately 10 nm, whereas that of the GR in CV-1 cells was ϳ6 nm. This small difference in binding affinity should, in fact, confer decreased, rather than increased, sensitivity to the GR in LLC-PK1 cells. Both values are within the range of binding affinities reported previously (2, 26, 27) using similar whole cell assays and incubation temperatures.
Chimeric receptor analysis
To further analyze the structural determinants of these observed cellular differences, a domain swap strategy was used in which the N-terminal domains of the receptors were exchanged to produce the chimeric receptors GRnMR and MRnGR. The characteristics of these chimeras in response to cortisol were compared in the CV-1 and LLC-PK1 cells (Fig.  4) . In CV-1 cells, maximal transactivation by GRnMR was almost double that by GR in the same cell line, whereas MRnGR activity was even less than that by MR (Table 2) ; these findings are in agreement with previous reports (2, 5) , which demonstrate that the enhanced transactivation by the GR is due to the greater activity of the N-terminus of the GR than that of the corresponding region of the MR. MRnGR, like the MR itself, has greater transcriptional activity (21% of the maximal GR response) in LLC-PK1 cells than in CV-1 cells (9%; P Ͻ 0.05; Fig. 4 and Table 2 ), suggesting that the N-terminus of the MR is indeed more transcriptionally active in LLC-PK1 cells. Further, in both cell lines, MRnGR activity is approximately a third that of the MR; the similarity of response also suggests that the N-terminus of the MR plays an important role in the mediation of these cellular differ- ences in the relative magnitude of the MR to GR response. In contrast to CV-1 cells, transactivation by GRnMR in LLC-PK1 cells is only minimally higher (117%) than that induced by the GR itself (Fig. 4 and Table 2 ), suggesting that repression by the LBD of the GR in these cells is weaker than that in CV-1 cells, in which the activity of the N-terminus of the GR is markedly enhanced by the LBD of the MR.
In CV-1 cells, cortisol sensitivity for the chimeric receptors correlated best with that of the wild-type receptor contributing the LBD to the chimera. Although levels of transactivation were clearly different, the dose-response curves for MRnGR were close to that of the GR, whereas the doseresponse curves for GRnMR better resembled that of the MR (Fig. 4 and Table 2 ). This, however, was not the case for LLC-PK1 cells. Unexpectedly, a direct comparison of the dose-response curves of the chimeric receptors in CV-1 and LLC-PK1 cells (Fig. 4) demonstrated that cell-specific, receptor-specific ligand sensitivity was associated with the Nterminus of the receptor. The left shift seen for the GR in the LLC-PK1 cells (Fig. 1 ) was also observed with the chimeric receptor GRnMR that had the N-terminus in common with the GR (Fig. 4) , whereas ligand sensitivity of the chimera MRnGR, like that of the MR, was largely unaltered between cell lines. Hence, the cell-specific sensitivity of the responses of the GR to cortisol (and by inference to dexamethasone) was conferred not by the LBD, but by the N-terminus. This suggests a novel mechanism by which GR and MR specificity can be conferred in a particular cellular milieu where proteins or transcription factors can distinguish between the GR and the MR to mediate receptor-specific and cell-specific ligand sensitivity.
Discussion
Despite similarities in molecular structure (1), in vitro ligand binding (2) , and transactivation (2, 3, 5) , the functions of the GR and the MR can be clearly differentiated in vivo. Mechanisms extrinsic to the receptor, particularly inactivation of cortisol by 11␤HSD2 to protect the MR and differential tissue expression, are important in epithelial tissues, but do not fully account for differences elsewhere. Although there is functional overlap between mineralocorticoids and glucocorticoids, in that both are closely involved in salt and water reabsorption and perhaps in aspects of neural function, GR and MR are physiologically distinct in other ways. Unique receptor-specific effects in nonepithelial tissues (10 -12) as well as the considerable regional variation in the specificity and mechanisms of receptor action on ion transport in epithelial tissues (8, 9, 28, 29) suggest the involvement of other tissue-specific mechanisms in the determination of receptor specificity.
Cell-specific differences in transactivation by steroid receptors (17, 30, 31) (other than the MR) suggest that specificity may be conferred by cell-specific factors that interact with the receptor. GR-mediated transrepression of activating protein-1-mediated transactivation (17) , however, is the only example identified to date that distinguishes between the GR and the MR. Although the weaker transactivational response of the MR relative to that of the GR in vitro might be intrinsic to the receptor, potent mineralocorticoid effects in vivo (9, 10, 28) suggest, rather, that enhanced MR-mediated effects might occur in other contexts. Factors limiting the apparent magnitude and specificity of the MR response observed in experimental systems might include the use of relatively undifferentiated CV-1 or COS cells. By directly comparing cell lines chosen to reflect predominant sites of in vivo MR expression in epithelial and nonepithelial tissues, we have identified two major receptorspecific differences in MR and GR transactivation that may further increase the physiological diversity of the response: a marked enhancement of the maximal relative MR response in both LLC-PK1 and RN33B cell lines and altered ligand sensitivity of the transcriptional response. The transactivational response of the MR has previously been reported to be only 10 -20% that of the GR (2) (3) (4) (5) . In contrast, the magnitude of the maximal transcriptional response by cortisol-activated MR, relative to that by the GR, is significantly enhanced in both renal epithelial and nonepithelial neuronal cell lines. In Fig. 5 , the cortisol dose-response curves from Fig. 1 have been redrawn to more clearly illustrate the different patterns of relative MR-and GR-mediated transcription at any given concentration of cortisol in each cell line. This is the first demonstration that the magnitude of transactivation by the MR may, in the correct cellular context, approach that of the GR. Indeed, in LLC-PK1 cells at most cortisol concentrations the MR is a more powerful activator of the glucocorticoidresponsive MMTV promoter than is the GR (Fig. 5) . Although these are only relative differences, chimeric studies suggest that this enhancement of transactivation is indeed MR-, rather than GR-, specific and might reflect the role of MR-specific factors in tissues in which the MR has important physiological functions. Consistent with earlier studies demonstrating the importance of the N-terminus and the LBD in transactivation and ligand binding, respectively (32), comparative chimeric receptor analysis indicates that increased transactivation by the N-terminus of the MR, rather than repression by the LBD of the GR, is responsible for the relative enhancement of the MR response in LLC-PK1 cells. The identification of receptor-specific changes is indirect proof that the MR as well as the GR can be specifically distinguished by cellular factors intrinsic to mammalian cells, via the N-terminus, to confer MR vs. GR specificity. The biphasic response to cortisol with the MR in LLC-PK1 cells is difficult to explain; perhaps two unique coactivators with differing affinities for the liganded-MR mediate the transactivation.
The degree to which ligand sensitivity, as reflected in the transcriptional response, varied among the three cell lines was unexpected; cortisol maximally activates the GR in LLC-PK1 cells at concentrations 100-fold lower than those required in RN33Bcells. The consistent presence, magnitude, and bidirectional variability in GR sensitivity are distinct from previously described minor variations due to week to week variations in cell density (33) . These differences are not due to ligand inactivation by 11␤HSD. Although 11␤HSD activity has been reported in both CV-1 (25) and LLC-PK1 cells (24) , 50% of 11␤HSD2 activity is destroyed by the calcium phosphate method of transfection used (24) . In keeping with this, the 11␤HSD2 inhibitor carbenoxolone (at a dose that completely inhibits enzyme activity) (25) did not alter the sensitivity for cortisol-mediated GR transactivation in either cell line (data not shown), as previously reported in CV-1 cells (25) . Additionally, the differences we observed in altered GR sensitivity, particularly between LLC-PK1 and RN33B cells, persisted with dexamethasone, which is poorly metabolized by 11␤HSD (14) . Finally, the absence of parallel differences in MR sensitivity strongly argues against altered cortisol bioavailability. Although we cannot exclude the possibility that these differences might be due to the use of cell lines and receptors that derive from different species, this would seem a less likely explanation given the high degree of conservation of the receptors between species. Curiously, these cell-specific differences in ligand sensitivity of the GRmediated transcriptional response do not result from changes in binding affinity. We have, therefore, clearly demonstrated that independently of 11␤HSD2 activity, additional cellular factors, which also discriminate between the GR and the MR, play an important role in modulating ligand sensitivity.
The LBD determines ligand sensitivity within CV-1 cells, where the transcriptional response reflects the binding affinity of the ligand. Surprisingly, domain swap analysis suggests that intercellular variations in transcriptional sensitivity are instead conferred by the N-terminus. The dose-response curves of both the GR and GRnMR are shifted to the left in LLC-PK1 cells relative to those in CV-1 cells, whereas the dose-response curves of both MR and MRnGR differ very little between cell lines with regard to ligand sensitivity. Our demonstration that the variations in cortisol sensitivity occur at a step distal to ligand binding is unexpected. It could be conferred by cellular coactivators or by transcription factors that are thought to associate with steroid receptors via transactivation domains (32, 34) . This would be consistent with the observed receptor specificity and the association between the N-terminus and ligand sensitivity. A yeast cellular repressor, SSN6, has been reported that also alters ligand sensitivity without affecting ligand affinity for the receptor (35) . A tripartite model of steroid receptor function has been proposed by which the primary determinant of ligand potency is the binding affinity of the ligand to the receptor, which may be further modified by the interaction of the ligandreceptor complex with a third partner (coactivators/corepressors) (34) . Our observations are consistent with such a model by which the kinetics of the coactivator-receptor interaction are independent of those of the ligand-receptor interaction. Receptor-and cell-specific ligand sensitivity where the dose-response curve is shifted could be conferred by cellular proteins whose affinities differ between cell lines for the activated liganded GR.
The very different patterns of relative MR to GR response, regraphed in Fig. 5 , illustrate how permutations of tissue-and receptor-specific differences in ligand sensitivity and the magnitude of the response could expand the dynamic range to mediate relative specificity, particularly where the two receptors are colocalized, such as in the central nervous system.
